NASDAQ:REGN

CHECKMATE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CMPI and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 19, 2022
NASDAQ, Regeneron Pharmaceuticals, Telephone, Learning, Acquisition, GLOBE, Squire, P.C, Property management, Checkmate

On April 19, 2022, Checkmate announced that it had entered into an agreement to be acquired by Regeneron in a deal valued at approximately $250 million.

Key Points: 
  • On April 19, 2022, Checkmate announced that it had entered into an agreement to be acquired by Regeneron in a deal valued at approximately $250 million.
  • Pursuant to the merger agreement, Checkmate stockholders will receive $10.50 in cash for each share of Checkmate common stock owned.
  • Bragar Eagel & Squire is concerned that Checkmates board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Retrieved on: 
Tuesday, April 19, 2022

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.

Key Points: 
  • We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.
  • We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field.
  • Vidutolimod is an investigational therapy and has not been approved by U.S. Food and Drug Administration or any other regulatory agency.
  • Upon the successful completion of the tender offer, Regeneron will acquire all shares not acquired in the tender through a second-step merger.

(REGN Alert) Long Term Holders of Regeneron Contact Johnson Fistel for Information Regarding Investigation

Retrieved on: 
Wednesday, March 23, 2022
Regeneron Pharmaceuticals, GLOBE, Company, Physician, Medicare, LLP, NASDAQ, SAN, Patient, Pharmaceutical industry

Attorneys office filed suit against Regeneron.

Key Points: 
  • Attorneys office filed suit against Regeneron.
  • Regeneron allegedly paid these substantial sums only after confirming that the foundation needed the money to cover co-pays only for Eylea and not for competing drugs.
  • The companys payments would generate a handsome return on investment, or ROI, in the form of Medicare payments for Eylea.
  • Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws.

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Retrieved on: 
Monday, February 28, 2022

The interim data released today include 15 hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients treated across four single-ascending dose cohorts.

Key Points: 
  • The interim data released today include 15 hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients treated across four single-ascending dose cohorts.
  • These data suggest that treatment with a one-time, systemically delivered CRISPR-based investigational therapy has the potential to substantially reduce levels of a disease-causing protein.
  • Data from the ongoing, first-in-human study of NTLA-2001 demonstrated rapid, deep and durable reduction of serum TTR protein.
  • At 1.0 mg/kg, the highest dose level studied, patients with polyneuropathy reached a 93% mean serum TTR reduction by day 28.